glp-1 long-term safety Addressing patient concerns about the 'newness' and of GLP- 1 receptor agonists: A clinician's guide to counseling WHO recognizes GLP-1 medications for

The barrier defect in CeD is hypothesized to contribute to diarrhea by a paracellular flux of water and solutes (87)

10.1016/j.jand.2017.06.006 J Acad Nutr Diet

Consult your primary care physician before starting any GLP-1 therapy

Addressing Injection Phobia and Adherence Barriers Injection phobia is a real issue for some considering GLP-1 therapies

In addition, the GLP-1 agonists may make some drugs more aversive or unpleasant, says Luba Yammine, an associate professor of psychiatry at UTHealth Houston who is currently the principal investigator of a clinical trial evaluating a GLP-1 agonist as a potential treatment for smoking cessation and post-cessation weight management